

Table 7. Summary of fold change in ratios of antiviral: antiproliferative and Th1: antiproliferative potencies at each variant relative to IFN-con1

Variant	Backbone	M1	M2	M3	AV-Huh	Th1	AP	Fold AV:AP	Fold Th1:AP
B9.1.1	B9.1.1	ψ	ψ	ψ	94.2				
B9X12	B9.1.1	B9.1.2	ψ	ψ	134	326	69.6	68.7	15.5
B9X14	B9.1.1	ψ	ψ	B9.1.2	42.9	48.8	10.5	32.4	15.6
B9X15	B9.1.1	B9.1.2	B9.1.2	ψ	272	466	42.4	20.6	6.6
B9X16	B9.1.1	B9.1.2	ψ	B9.1.2	39.4	19.9	22.3	74.9	81.2
B9X17	B9.1.1	ψ	B9.1.2	B9.1.2	107	118	5.02	6.2	3.1
B9X18	B9.1.1	B9.1.2	B9.1.2	B9.1.2	77.5	69.6	9.58	16.4	10.0
B9.1.2	B9.1.2		B9.1.2	B9.1.2	135	92.4	6.15	6.0	4.8
B9X22	B9.1.2	ψ	B9.1.2	B9.1.2	89.5	159	8.48	12.5	3.9
B9X23	B9.1.2	B9.1.2	ψ	B9.1.2	57.4	35.4	8.32	19.2	17.0
B9X24	B9.1.2	B9.1.2	B9.1.2	ψ	174	0	14.9	11.3	0.0
B9X25	B9.1.2	ψ	ψ	B9.1.2	49.2	39.5	9.91	26.6	18.2
B9X26	B9.1.2	ψ	B9.1.2	B9.1.2	158	76.8	20	16.7	18.9
B9X27	B9.1.2	B9.1.2	ψ	ψ	125	92.6	57.3	60.6	44.9
B9X28	B9.1.2	ψ	ψ	ψ	46.8	49.6	17.2	48.6	25.1
IFN-α2b					1180	834	4.42		
IFN-con1					553	303	4.18	1.0	1.0

The mean potencies of each of the B9X variants, IFN α -2b and IFN-con1, in the Huh antiviral (AV-Huh), Th1-inducing (Th1), and Daudi antiproliferation (AP) assays are given (pg/ml). The fold increase in ratio of AV:AP potency relative to IFN-con1 was calculated for B9X12 by taking the ratio of AV:AP EC50s for IFN-con1 and dividing by the ratio of AV:AP EC50s for B9X12. The fold increases in ratio of AV:AP and Th1:AP potencies relative to IFN-con1 were calculated similarly for the other variants. The parental origin of three sequence motifs corresponding to the pseudogene-derived sequences (Ψ) in B9.1.1 are indicated (M1, residue 48; M2, residues 52-60; M3, residues 134 and 142).